Replies to post #340043 on Amarin Corp Plc (AMRN)

[sts66]

AMRN presented multiple post-hoc studies at the ACC21 over the weekend - so they're meaningless too?

https://investor.amarincorp.com/news-releases/news-release-details/amarin-highlights-multiple-scientific-findings-vascepar

Don't know if this one was post-hoc (likely it was), but wowza, some amazing new data from EVAP - dunno how this compares to the originally reported -19% reduction in plaque - is it something else they measured?

EFFECT OF ICOSAPENT ETHYL ON PERCENT ATHEROMA VOLUME IN PATIENTS WITH ELEVATED TRIGLYCERIDES ON STATIN THERAPY: INSIGHTS FROM THE EVAPORATE TRIAL” – presented on behalf of all authors by Suvasini Lakshmanan, M.D., M.S., The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA

Highlights: The EVAPORATE trial sought to examine the anti-atherosclerotic effects of icosapent ethyl (IPE) (4g/day) as an adjunct to statins in patients with residually elevated triglycerides on serial Coronary Computed Tomography Angiography (CCTA) over 18 months. Percent atheroma volume (PAV) is identified as a robust prognostic marker of whole-heart atherosclerotic plaque characterization with CCTA. Sixty-eight patients (54% male, age 57.4± 9.2 years) who completed 18-month follow-up and with interpretable images were included in the coronary plaque analysis that revealed that those on IPE have 55% lower total plaque (TP) PAV and 61% lower total non-calcified plaque (TNCP) PAV, compared with placebo (p<0.01). IPE demonstrated significant reductions in coronary plaque burden on CCTA compared with placebo over 18 months. EVAPORATE provides crucial mechanistic insights on whole-heart atherosclerotic plaque burden that may explain the clinical benefits of IPE in REDUCE-IT.